stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 37 | 37 | 367 | +215.6% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | 0 | (29) | (66) | (108) | (157) | (211) | (259) | (413) | (505) | (539) | +479.0% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (29) | (66) | (107) | (157) | (211) | (259) | (414) | (506) | (538) | +479.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1.29) | (1.54) | (1.22) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) | (2.82) | +11.5% | ||||||
| Cash flow | — | 0.00 | (1.29) | (1.24) | (0.95) | (0.97) | (1.53) | (1.55) | (2.48) | (2.23) | (2.02) | n/m | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | 0.00 | (1.29) | (1.24) | (0.95) | (0.97) | (1.53) | (1.55) | (2.48) | (2.23) | (2.02) | n/m | ||||||
| Book value | — | 0.00 | 0.33 | 2.18 | 4.46 | 4.28 | 2.95 | 4.47 | 4.67 | 4.67 | 3.58 | +169.1% | ||||||
| Shares, m | — | 14 | 22 | 43 | 88 | 110 | 123 | 138 | 152 | 182 | 186 | +37.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (29) | (53) | (83) | (106) | (188) | (214) | (376) | (407) | (414) | +46.2% | |||||
| Capex | — | — | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | (1) | (23.5%) | ||||||
| Free cash flow | — | — | (29) | (53) | (84) | (106) | (188) | (215) | (377) | (407) | (414) | +46.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 6 | 94 | 390 | 468 | 361 | 617 | 699 | 844 | 734 | n/m | |||||
| Net debt | — | 0 | (7) | (101) | (400) | (494) | (377) | (635) | (714) | (902) | (798) | +271.2% | ||||||
| Shareholders’ equity | — | 0 | 7 | 94 | 391 | 470 | 362 | 618 | 707 | 853 | 735 | +269.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (0.01) | (401.87) | (107.76) | (41.17) | (33.78) | (45.79) | (48.37) | (57.37) | (58.34) | (71.10) | (58.3) pt | |||||
| ROIC | — | 0.00 | (5,018.54) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | (0.01) | (776.77) | (130.93) | (44.25) | (36.39) | (50.69) | (52.91) | (62.46) | (64.82) | (80.10) | (64.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 17 | 42 | 68 | 124 | 164 | 207 | 362 | 315 | — | +51.7% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Business profile
Immunovant, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals, Inc. | $6.5B | — (loss-making) | — (loss-making) | −40.73% (below 0%: shrinking) | n/m | +299.29% (above 0%: growing) | 98.98% | (38.18%) | Compare |
| MIRM Mirum Pharmaceuticals, Inc. | $6.1B | — (loss-making) | — (loss-making) | +39.63% (above 0%: growing) | n/m | −114.22% (below 0%: shrinking) | 81.06% | (32.17%) | Compare |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 116× | 88.3× | −31.80% (below 0%: shrinking) | n/m | −268.45% (below 0%: shrinking) | 96.63% | (20.01%) | Compare |
| IMVT Immunovant, Inc. | $5.9B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | |
| BLTE Belite Bio, Inc. Sponsored ADR | $5.8B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.7B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| KOD Kodiak Sciences Inc. | $5.7B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.5B | — (loss-making) | 42.2× | +69.57% (above 0%: growing) | n/m | +90.28% (above 0%: growing) | 93.39% | 7.02% | Compare |
| MANE Veradermics Incorporated | $5.4B | — (loss-making) | — | — | n/m | −8.81% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $5.8B | — | — | +39.63% | — | −21.33% | 87.23% | (10.00%) |
Pay and ownership Proxy statement filed 22 July 2026
Ownership
Directors and executive officers, together
1.90%
Roivant Sciences Ltd.
54.90%
FMR LLC
7.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement
Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases, in which the immune system attacks the body’s own tissues. It has never generated revenue and does not yet sell a medicine. Its chief executive officer is Eric Venker.
The company is focused on IMVT-1402, also called imeroprubart, an investigational antibody designed for diseases driven by harmful immunoglobulin G, or IgG, antibodies. A protein called FcRn normally helps protect IgG antibodies from being broken down. IMVT-1402 blocks FcRn, allowing more of those antibodies to be degraded rather than returned to circulation.